Real-world data for effectiveness and safety of palopegteriparatide in patients with chronic hypoparathyroidism: the PaTH REAL study.

Yavropoulou MP, Tournis S, Chondrogianni ME, Florakis D, Chrisoulidou A, Adamidou F, Efstathiadou Z, Giagourta E, Giannou A, Stratigou T, Markou A, Vasileiou V and 7 more

Show all authors

Ntali G, Balodimou C, Kalogeris N, Koloutsou ME, Makras P, Vryonidou A, Kassi E

European journal of endocrinology1 Aug 2026

PMID42656047DOI10.1093/ejendo/lvag145PepBankPUB-42656047

Publisher page PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanObservational studyEfficacy outcome
In adults with hypoparathyroidism, palopegteriparatide treatment was linked to calcium increasing from 8.14 ± 0.73 to 8.99 ± 0.94 mg/dL (P < .001).
In plain wordsIn adults with hypoparathyroidism, palopegteriparatide treatment was linked to increased calcium from baseline.
Peptide
Palopegteriparatide
Outcome
IncreaseAlbumin-adjusted calcium
Study
n = 92
Outcome group
Electrolyte balance · Endocrine and hormones
Studied dose
Dose not stated · median 6.5 months (range 2-14)As given in this study (human).
Measurements
Albumin-adjusted calcium
8.14 mg/dL
baseline, SD 0.73
Albumin-adjusted calcium
8.99 mg/dL
follow-up, SD 0.94
P value
< 0.001
calcium change from baseline
Source sentences
Summary
Albumin-adjusted calcium increased from 8.14 ± 0.73 to 8.99 ± 0.94 mg/dL, and magnesium from 1.79 ± 0.17 to 1.96 ± 0.17 mg/dL (both P < .001).
2 context sentences(design, population, supporting numbers)
Summary · context
Multicenter prospective cohort study conducted in tertiary referral hospitals.
Summary · context
Ninety-two adults with HypoPT (79 females, 13 males), previously treated with recombinant human PTH (1-84) or conventional therapy, initiated palopegteriparatide according to the National Hellenic Guidelines for the management of HypoPT.
Report a problemFND-4265604701
02HumanObservational studyEfficacy outcome
In adults with hypoparathyroidism, palopegteriparatide treatment was linked to magnesium increasing from 1.79 ± 0.17 to 1.96 ± 0.17 mg/dL (P < .001).
In plain wordsIn adults with hypoparathyroidism, palopegteriparatide treatment was linked to increased magnesium from baseline.
Peptide
Palopegteriparatide
Outcome
IncreaseMagnesium
Study
n = 92
Outcome group
Electrolyte balance · Endocrine and hormones
Studied dose
Dose not stated · median 6.5 months (range 2-14)As given in this study (human).
Measurements
Magnesium
1.79 mg/dL
baseline, SD 0.17
Magnesium
1.96 mg/dL
follow-up, SD 0.17
P value
< 0.001
magnesium change from baseline
Source sentences
Summary
Albumin-adjusted calcium increased from 8.14 ± 0.73 to 8.99 ± 0.94 mg/dL, and magnesium from 1.79 ± 0.17 to 1.96 ± 0.17 mg/dL (both P < .001).
2 context sentences(design, population, supporting numbers)
Summary · context
Multicenter prospective cohort study conducted in tertiary referral hospitals.
Summary · context
Ninety-two adults with HypoPT (79 females, 13 males), previously treated with recombinant human PTH (1-84) or conventional therapy, initiated palopegteriparatide according to the National Hellenic Guidelines for the management of HypoPT.
Report a problemFND-4265604702
03HumanObservational studyEfficacy outcome
In adults with hypoparathyroidism, palopegteriparatide treatment was linked to phosphate decreasing from 4.74 ± 0.97 to 4.02 ± 0.63 mg/dL (P < .001).
In plain wordsIn adults with hypoparathyroidism, palopegteriparatide treatment was linked to decreased phosphate from baseline.
Peptide
Palopegteriparatide
Outcome
DecreasePhosphate
Study
n = 92
Outcome group
Electrolyte balance · Endocrine and hormones
Studied dose
Dose not stated · median 6.5 months (range 2-14)As given in this study (human).
Measurements
Phosphate
4.74 mg/dL
baseline, SD 0.97
Phosphate
4.02 mg/dL
follow-up, SD 0.63
P value
< 0.001
phosphate change from baseline
Source sentences
Summary
Phosphate decreased from 4.74 ± 0.97 to 4.02 ± 0.63 mg/dL (P < .001), Ca × P product from 38.27 ± 6.92 to 36.04 ± 6.55 mg2/dL2 (P = .017), and 24-hour urinary calcium from 245.7 ± 125.5 to 164.5 ± 88.3 mg/24 h (P < .001).
2 context sentences(design, population, supporting numbers)
Summary · context
Multicenter prospective cohort study conducted in tertiary referral hospitals.
Summary · context
Ninety-two adults with HypoPT (79 females, 13 males), previously treated with recombinant human PTH (1-84) or conventional therapy, initiated palopegteriparatide according to the National Hellenic Guidelines for the management of HypoPT.
Report a problemFND-4265604703
04HumanObservational studyEfficacy outcome
In adults with hypoparathyroidism, palopegteriparatide treatment was linked to Ca × P decreasing from 38.27 ± 6.92 to 36.04 ± 6.55 mg2/dL2 (P = .017).
In plain wordsIn adults with hypoparathyroidism, palopegteriparatide treatment was linked to a decreased calcium-phosphate product from baseline.
Peptide
Palopegteriparatide
Outcome
DecreaseCalcium-phosphate product
Study
n = 92
Outcome group
Electrolyte balance · Endocrine and hormones
Studied dose
Dose not stated · median 6.5 months (range 2-14)As given in this study (human).
Measurements
Calcium-phosphate product
38.27 mg2/dL2
baseline, SD 6.92
Calcium-phosphate product
36.04 mg2/dL2
follow-up, SD 6.55
P value
0.017
Ca x P product change from baseline
Source sentences
Summary
Phosphate decreased from 4.74 ± 0.97 to 4.02 ± 0.63 mg/dL (P < .001), Ca × P product from 38.27 ± 6.92 to 36.04 ± 6.55 mg2/dL2 (P = .017), and 24-hour urinary calcium from 245.7 ± 125.5 to 164.5 ± 88.3 mg/24 h (P < .001).
2 context sentences(design, population, supporting numbers)
Summary · context
Multicenter prospective cohort study conducted in tertiary referral hospitals.
Summary · context
Ninety-two adults with HypoPT (79 females, 13 males), previously treated with recombinant human PTH (1-84) or conventional therapy, initiated palopegteriparatide according to the National Hellenic Guidelines for the management of HypoPT.
Report a problemFND-4265604704
05HumanObservational studyEfficacy outcome
In adults with hypoparathyroidism, palopegteriparatide treatment was linked to urinary calcium decreasing from 245.7 ± 125.5 to 164.5 ± 88.3 mg/24 h (P < .001).
In plain wordsIn adults with hypoparathyroidism, palopegteriparatide treatment was linked to decreased urinary calcium from baseline.
Peptide
Palopegteriparatide
Outcome
Decrease24-hour urinary calcium
Study
n = 92
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · median 6.5 months (range 2-14)As given in this study (human).
Measurements
24-hour urinary calcium
245.7 mg/24 h
baseline, SD 125.5
24-hour urinary calcium
164.5 mg/24 h
follow-up, SD 88.3
P value
< 0.001
urinary calcium change from baseline
Source sentences
Summary
Phosphate decreased from 4.74 ± 0.97 to 4.02 ± 0.63 mg/dL (P < .001), Ca × P product from 38.27 ± 6.92 to 36.04 ± 6.55 mg2/dL2 (P = .017), and 24-hour urinary calcium from 245.7 ± 125.5 to 164.5 ± 88.3 mg/24 h (P < .001).
2 context sentences(design, population, supporting numbers)
Summary · context
Multicenter prospective cohort study conducted in tertiary referral hospitals.
Summary · context
Ninety-two adults with HypoPT (79 females, 13 males), previously treated with recombinant human PTH (1-84) or conventional therapy, initiated palopegteriparatide according to the National Hellenic Guidelines for the management of HypoPT.
Report a problemFND-4265604705
06HumanObservational studyEfficacy outcome
In adults with hypoparathyroidism, palopegteriparatide treatment was linked to a marked reduction in daily pill burden.
In plain wordsIn adults with hypoparathyroidism, palopegteriparatide treatment was linked to fewer daily pills than at baseline.
Peptide
Palopegteriparatide
Outcome
DecreaseDaily pill burden
Study
n = 92
Outcome group
Conventional therapy requirements · Endocrine and hormones
Studied dose
Dose not stated · median 6.5 months (range 2-14)As given in this study (human).
Source sentences
Summary
Daily pill burden was markedly reduced, and 58% of patients achieved independence from calcium supplements and alfacalcidol after a median of 30 days.
2 context sentences(design, population, supporting numbers)
Summary · context
Multicenter prospective cohort study conducted in tertiary referral hospitals.
Summary · context
Ninety-two adults with HypoPT (79 females, 13 males), previously treated with recombinant human PTH (1-84) or conventional therapy, initiated palopegteriparatide according to the National Hellenic Guidelines for the management of HypoPT.
Report a problemFND-4265604706
07HumanObservational studyEfficacy outcome
In adults with hypoparathyroidism, 58% achieved independence from calcium and alfacalcidol after a median of 30 days during palopegteriparatide treatment.
In plain wordsIn adults with hypoparathyroidism, 58% no longer needed calcium or alfacalcidol after a median of 30 days during palopegteriparatide treatment.
Peptide
Palopegteriparatide
Outcome
Not applicableIndependence from calcium and alfacalcidol
Study
n = 92
Outcome group
Conventional therapy requirements · Endocrine and hormones
Studied dose
Dose not stated
Measurements
Patients independent of calcium supplements and alfacalcidol
58%
real-world cohort
Time to independence (median)
30 days
patients achieving independence
Source sentences
Summary
Daily pill burden was markedly reduced, and 58% of patients achieved independence from calcium supplements and alfacalcidol after a median of 30 days.
2 context sentences(design, population, supporting numbers)
Summary · context
Multicenter prospective cohort study conducted in tertiary referral hospitals.
Summary · context
Ninety-two adults with HypoPT (79 females, 13 males), previously treated with recombinant human PTH (1-84) or conventional therapy, initiated palopegteriparatide according to the National Hellenic Guidelines for the management of HypoPT.
Report a problemFND-4265604707
08HumanObservational studySafety outcome
In adults with hypoparathyroidism receiving palopegteriparatide, adverse events were mostly mild and transient.
In plain wordsIn adults with hypoparathyroidism receiving palopegteriparatide, adverse events were mostly mild and transient.
Peptide
Palopegteriparatide
Outcome
Not applicableAdverse event severity and course
Study
n = 92
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · median 6.5 months (range 2-14)As given in this study (human).
Source sentences
Summary
Adverse events were mostly mild and transient.
2 context sentences(design, population, supporting numbers)
Summary · context
Multicenter prospective cohort study conducted in tertiary referral hospitals.
Summary · context
Ninety-two adults with HypoPT (79 females, 13 males), previously treated with recombinant human PTH (1-84) or conventional therapy, initiated palopegteriparatide according to the National Hellenic Guidelines for the management of HypoPT.
Report a problemFND-4265604708

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT07299838

Palopegteriparatide in Chronic Hypoparathyroidism

National and Kapodistrian University of Athensn = 901 Jun 2024 to 23 Oct 2025

Hypoparathyroidism

Trial page ClinicalTrials.govUpdated 26 Jan 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 2
27 Oct 2026, 16:37 UTC
Study data updated · source update from Europe PMC
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC